Literature DB >> 24664359

Vitamin D deficiency in patients with malignancy in Brisbane.

Adam Morton1, Janet Hardy, Anthony Morton, Angela Tapuni, Helen Anderson, Ngaire Kingi, Catherine Shannon.   

Abstract

PURPOSE: This study aims to investigate the prevalence and factors predictive of vitamin D deficiency in patients with malignancy in Brisbane, Australia (latitude 27° S).
METHODS: This is a prospective cross-sectional study measuring serum levels of 25-hydroxyvitamin D (25-OHD) in 100 subjects with non-haematological cancer at least 18 years of age not taking vitamin D supplements attending a day oncology unit and oncology/palliative care inpatient ward in Brisbane, Australia.
RESULTS: Thirty-seven per cent of outpatient and 49 % of inpatient subjects respectively were vitamin D deficient. Functional status was predictive of low vitamin D levels.
CONCLUSION: There was a high prevalence of vitamin D deficiency in patients with cancer in Brisbane, Australia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24664359     DOI: 10.1007/s00520-014-2218-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  24 in total

1.  Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study.

Authors:  Robin M Daly; Claudia Gagnon; Zhong X Lu; Dianna J Magliano; David W Dunstan; Ken A Sikaris; Paul Z Zimmet; Peter R Ebeling; Jonathan E Shaw
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

2.  Vitamin D deficiency in an Australian inpatient hospice population.

Authors:  Timothy To
Journal:  J Pain Symptom Manage       Date:  2010-11-03       Impact factor: 3.612

3.  Variability in vitamin D assays impairs clinical assessment of vitamin D status.

Authors:  J K C Lai; R M Lucas; E Banks; A-L Ponsonby
Journal:  Intern Med J       Date:  2012-01       Impact factor: 2.048

4.  Vitamin D and health in adults in Australia and New Zealand: a position statement.

Authors:  Caryl A Nowson; John J McGrath; Peter R Ebeling; Anjali Haikerwal; Robin M Daly; Kerrie M Sanders; Markus J Seibel; Rebecca S Mason
Journal:  Med J Aust       Date:  2012-06-18       Impact factor: 7.738

Review 5.  Vitamin D insufficiency.

Authors:  Tom D Thacher; Bart L Clarke
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

Review 6.  Vitamin D supplementation and cancer: review of randomized controlled trials.

Authors:  Matteo Lazzeroni; Davide Serrano; Stefan Pilz; Sara Gandini
Journal:  Anticancer Agents Med Chem       Date:  2013-01       Impact factor: 2.505

7.  Vitamin D deficiency and insufficiency among patients with prostate cancer.

Authors:  Donald L Trump; Manpreet K Chadha; Annette Y Sunga; Marwan G Fakih; Umeer Ashraf; Carrie G Silliman; Bruce W Hollis; Mary K Nesline; Lili Tian; Wei Tan; Candace S Johnson
Journal:  BJU Int       Date:  2009-04-04       Impact factor: 5.588

8.  Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial.

Authors:  R Jorde; M Sneve; Y Figenschau; J Svartberg; K Waterloo
Journal:  J Intern Med       Date:  2008-09-10       Impact factor: 8.989

9.  A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases.

Authors:  Eitan Amir; Christine E Simmons; Orit C Freedman; George Dranitsaris; David E C Cole; Reinhold Vieth; Wei S Ooi; Mark Clemons
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

10.  Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series.

Authors:  Christa Rainville; Yasir Khan; Glenn Tisman
Journal:  Cases J       Date:  2009-07-21
View more
  1 in total

1.  25-Hydroxyvitamin D in Cancer Patients Admitted to Palliative Care: A Post-Hoc Analysis of the Swedish Trial 'Palliative-D'.

Authors:  Maria Helde Frankling; Caritha Klasson; Linda Björkhem-Bergman
Journal:  Nutrients       Date:  2022-01-29       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.